Nivolumab for solid tumors and epithelioid sarcoma
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug (nivolumab) in children and adults with certain hard-to-treat solid tumors. It may help if standard treatments haven't worked or aren't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older
- You have either a pediatric solid tumor (any type) or epithelioid sarcoma that cannot be removed by surgery
- Standard treatments have not worked, are not available, or are not right for you
- You have at least one tumor that can be measured on a scan
- You are able to get up and about (fully active or with some restriction)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
This trial tests an infusion of activated NK cells (a type of immune cell) to treat sarcomas that are still detectable or not responding well to standard treatment. If you qualify, you may receive this cell therapy while doctors closely check your organ function and heart strength.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or haven't responded to standard treatment. The goal is to see if this drug mix can shrink or control the tumors.
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
This trial tests a new drug called nenocorilant combined with nivolumab (an immunotherapy) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Hear when a new Pediatric Malignant Solid Tumor and Epithelioid Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.